The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01, R21 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices is not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery.
This FOA is not specific for any one or group of pain conditions. Projects to identify novel targets for acute pain, chronic pain, migraine, other headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, post stroke pain, orofacial pain, etc. will be considered. Projects to identify novel targets for a combination of chronic overlapping pain conditions or for specific pathological conditions will be considered. Projects that seek to identify novel targets in specific populations such as women, children, older adults or other underrepresented groups will also be responsive to this FOA.
Although this funding opportunity uses the R01 grant mechanism, it runs in parallel with a program announcement of identical scientific scope, RFA-NS-18-042, which uses the R21 grant mechanism.
- Letter of Intent Due Date(s): 30 days prior to the application due date.
- Application Due Date(s): November 27, 2018; February 11, 2019; July 11, 2019; November 12, 2019
- AIDS Application Due Date(s): November 27, 2018; February 11, 2019; July 11, 2019; November 12, 2019
RFA-NS-18-043 Expiration Date November 13, 2019